Henlius Biotech Strikes Licensing Deal with Dr. Reddy's for Myeloma Drug
MT Newswires Live02-07
Shanghai Henlius Biotech (HKG:2696) agreed to license its anti-cancer injection HLX15 to Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) in the US and 42 European countries.
HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection and a daratumumab biosimilar developed by the company. It is indicated for treating multiple myeloma.
Under the agreement, Dr. Reddy's Laboratories is granted the license to manufacture and commercialize HLX15 in subcutaneous and intravenous forms across 43 markets.
Dr. Reddy's Laboratories will make an upfront payment of $33 million, plus $98.6 million in milestone payments and 8% of the annual net sales as royalties, a Thursday Hong Kong bourse filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
